Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Havrda, Marek
13  Ergebnisse:
Personensuche X
?
1

Well-being impact assessment of artificial intelligence – A..:

Havrda, Marek ; Klocek, Adam
Evaluation and Program Planning.  99 (2023)  - p. 102294 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Enhanced well-being assessment as basis for the practical i..:

, In: 2020 IEEE International Conference on Systems, Man, and Cybernetics (SMC),
Havrda, Marek ; Rakova, Bogdana - p. 2754-2761 , 2020
Link: https://doi.org/10.1109/..
 
?
3

Artificial Intelligence's Role in Community Engagement with..:

Havrda, Marek
International Journal of Community Well-Being.  3 (2020)  4 - p. 437-441 , 2020
Link: https://doi.org/10.1007/..
 
?
4

The Czech Republic: the Case of Delayed Transformation:

, In: Corporate Governance in a Changing Economic and Political Environment,
Havrda, Marek - p. 121-143 , 2003
Link: https://doi.org/10.1057/..
 
?
5

Enhanced well-being assessment as basis for the practical i..:

Havrda, Marek ; Rakova, Bogdana
http://arxiv.org/abs/2007.14826.  , 2020
Link: http://arxiv.org/abs/200..
 
?
6

Omezování elektromagnetických emisí ; Reduction of electrom..:

Havrda, Marek
47249.  , 2011
Link: http://hdl.handle.net/11..
 
?
7

The most common founder pathogenic variant c.868G > A (p.Va..:

Thomasová, Dana ; Zelinová, Michaela ; Libik, Malgorzata...
Frontiers in Medicine.  10 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
8

The most common founder pathogenic variant c.868G > A (p.Va..:

Thomasová, Dana ; Zelinová, Michaela ; Libik, Malgorzata...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10759319/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

The most common founder pathogenic variant c.868G > A (p.Va..:

Dana Thomasová ; Michaela Zelinová ; Malgorzata Libik...
https://www.frontiersin.org/articles/10.3389/fmed.2023.1320054/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
10

Table_1_The most common founder pathogenic variant c.868G >..:

Dana Thomasová ; Michaela Zelinová ; Malgorzata Libik...
doi:10.3389/fmed.2023.1320054.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
11

Table_1_The most common founder pathogenic variant c.868G >..:

Dana Thomasová ; Michaela Zelinová ; Malgorzata Libik...
doi:10.3389/fmed.2023.1320054.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
12

Table_2_The most common founder pathogenic variant c.868G >..:

Dana Thomasová ; Michaela Zelinová ; Malgorzata Libik...
doi:10.3389/fmed.2023.1320054.s002.  , 2023
Link: https://doi.org/10.3389/..
 
?
13

Table_2_The most common founder pathogenic variant c.868G >..:

Dana Thomasová ; Michaela Zelinová ; Malgorzata Libik...
doi:10.3389/fmed.2023.1320054.s002.  , 2023
Link: https://doi.org/10.3389/..
 
1-13